Cargando…
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
In recent years, new treatment options for malignant melanoma patients have enhanced the overall survival for selected patients. Despite new hope, most melanoma patients still relapse with drug-resistant tumors or experience intrinsic resistance to the therapy. Therefore, novel treatment modalities...
Autores principales: | Fleten, Karianne G, Flørenes, Vivi Ann, Prasmickaite, Lina, Hill, Oliver, Sykora, Jaromir, Mælandsmo, Gunhild M, Engesæter, Birgit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149582/ https://www.ncbi.nlm.nih.gov/pubmed/28028438 http://dx.doi.org/10.1038/cddiscovery.2016.81 |
Ejemplares similares
-
Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
por: Engesæter, Birgit, et al.
Publicado: (2012) -
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
por: Seip, Kotryna, et al.
Publicado: (2016) -
AXL inhibition improves BRAF-targeted treatment in melanoma
por: Nyakas, Marta, et al.
Publicado: (2022) -
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
por: Magnussen, Gry Irene, et al.
Publicado: (2015) -
Aldehyde Dehydrogenase (ALDH) Activity Does Not Select for Cells with Enhanced Aggressive Properties in Malignant Melanoma
por: Prasmickaite, Lina, et al.
Publicado: (2010)